Loading patent…
AssigneePharmacosmos Holding A/S
InventorsHans Berg Andreasen, Lars Christensen
Estimating the term…
An iron-dextrin compound for treatment of iron deficiency anaemia comprising hydrogenated dextrin having a weight average molecular weight equal to or less than 3,000 Dalton and a number average molecular weight equal to or higher than 400 Daltons, in stable association with ferric oxyhydroxide. As the molecular weight of the dextrin must be narrow it is another important feature of the invention that the 10% fraction of the dextrins having the highest molecular weight has an average molecular weight of less than 4500 Daltons, and that 90% of the dextrins are having molecular weights of less than 3000 Daltons. It is further important that the 10% fraction having the lowest molecular weight has a weight average molecular weight of 340 Daltons or more.
Iron dextrin compound consisting of hydrogenated dextrin in stable association with ferric oxohydroxide, characterized in that, said hydrogenated dextrin has a weight average molecular weight (Mw) equal to or less than 3,000 Daltons and a number average molecular weight higher than or equal to 400 Daltons, wherein the 10% fraction of said hydrogenated dextrin having the highest molecular weight has a weight average molecular weight of less than 4,500 Daltons, and that 90% of the dextrins are having a molecular weight of less than 3,500 Daltons, and wherein the 10% fraction of said hydrogenated dextrin having the lowest molecular weight has a weight average molecular weight of 340 Daltons or more.
Dependencies are inferred from the claim text.